FemTech Insight Digest

Premature Menopause and CHD Risk

• 🔥 40% Higher Lifetime Risk: A new study published in JAMA Cardiology links premature menopause before age 40...

JAMA Cardiology study of ~10,000 women shows premature menopause (before 40) ties to 40% higher lifetime coronary heart disease risk.

• Racial gap:...

Key diagnostic breakthrough from HerAnova Lifesciences:

• 80% sensitivity, 97.5% specificity in 298-patient study (177 confirmed cases)
• Detects...

Emerging research spotlights FemTech diagnostics/therapy potential:

• Vulvodynia subtypes: Hormonally-driven cases show 70% response to...

FemTech Funding Rounds

• 🔥 Diamens Pre-Seed: Austrian startup Diamens raised a six-figure pre-seed round to develop and clinically validate a...

Key practical strategies from Dr. Wynne for family physicians:

• Screening essentials: Use Mini-Cog during Medicare wellness visits or caregiver...

Rising trend in menopause integration reveals support gaps:

• Health system hubs now open across all Welsh health boards, localizing menopause care
  -...

Malama Health secured $9.2 million in seed funding to scale its doula-led maternal care platform for Medicaid-insured women. This underscores investor backing for reimbursement-relevant innovations serving underserved maternal health segments.

Key developments signaling faster, scalable diagnostics:

• Austrian startup Diamens raises six-figure pre-seed to advance menstrual blood-based...

Hologic Index reveals persistent global gaps despite modest screening upticks, spotlighting urgent need for diagnostic FemTech in under-screened...

• Patient odyssey: 33yo endured 20-year diagnostic delay from puberty pain, gaslighting, masked symptoms via birth control, to 23-lesion surgery.
  -...

Fund That Tiger launches with $10M target for Clemson alumni-led startups, offering a blueprint for university-affinity funds in emerging markets.

-...

Compliance algorithms systematically label women’s health startups—from fertility apps to sexual wellness brands—as high-risk, creating a global financial blockade. This underscores systemic barriers as a key non-dilutive funding risk for FemTech.

Exits & Non-Dilutive Funding

• 🔥 Venture Catalysts 9.6x Exit from Pee Safe: Early-stage investor Venture Catalysts exited women’s hygiene startup...

Women's hygiene FemTech exit signals:

• Early-stage investor Venture Catalysts exits Pee Safe with 9.6x return
• Follows $32M Series C led by...

• Persistent delays: Women rely on private healthcare for MRI confirmation of severe Stage 4 endometriosis, amid claims of 'systemic misogyny'.
• NHS...

Key findings from REACT-Long Covid Study (14,234 women aged 45-55):

• Self-reported surge: Perimenopausal women had 31% higher odds of cognitive...

• SBIR/STTR essentials: U.S. government R&D programs via NIH and 10 other agencies award $4B+ annually, non-dilutive, up to $275K Phase I...

Regulatory Challenges in Women's Sexual Health

• 🔥 The Pink Pill Documentary: New documentary 'The Pink Pill' exposes the long battle to bring...

Validated surveys assessed needs of 40 HTA doers, users, and potential trainers to inform training program design – a replicable strategy for building sustainable HTA capacity essential to reimbursement and integration.